Brought to you by 
Pfizer to market 38 generic cancer drugs for Strides Arcolab
19 May 2010
Executive Summary
In its second agreement with Pfizer Inc. this year, Indian firm Strides Arcolab Ltd. has licensed the Big Pharma rights to commercialize 38 generic cancer drugs in the EU, Canada, Australia, New Zealand, Japan, and Korea. In addition, Pfizer gets US rights to niche sterile injectables.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer to market 38 generic cancer drugs for Strides Arcolab
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice